In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative DiseasesShots:The P-I clinical trials evaluate NVG-291 vs PBO in healthy volunteers with neurodegenerative diseases such as AD and MS. The interim results were presented at ANA 146th annual meetingThe interim…
